| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_53e6a78e039b79ebaaec9938f9a755a3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc1fc78315989c6b5f4055421e10f11c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef6fe962eaf69a4d4aa74f0bf67b50c4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_69ece09bafee7e0c49d1f7951a3faa2c |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-22 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N9-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate |
1995-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f17616a227f5982c5c0f8c364d5b4e01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2ecec83177ac3fb8457268581fbe3194
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3fd943c9dde8886d337187732bcc1b7 |
| publicationDate |
1996-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9626278-A1 |
| titleOfInvention |
HUMAN DNase I VARIANTS |
| abstract |
The present invention relates to amino acid sequence variants of human DNase I that have reduced binding affinity for actin. The invention provides nucleic acid sequences encoding such actin-resistant variants, thereby enabling the production of these variants in quantities sufficient for clinical use. The invention also relates to pharmaceutical compositions and therapeutic uses of actin-resistant variants of human DNase I. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9603906-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-6391607-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9603907-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2013114371-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9747751-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-7118901-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1433842-A1 |
| priorityDate |
1995-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |